JAKARTA - PT Kalbe Farma Tbk (KLBF) posted a net profit of IDR 3.24 trillion in 2024, up 17.13% from IDR 2.76 trillion in 2023. The realisation of the increase in profit was due to revenue growth, especially sales in the domestic market.

In the 2025 Financial Report published on Friday (28/3), Bernadette Ruth Irawati Setiady, President Director of KLBF said that the company recorded sales of IDR32.62 trillion, up 7.15% from IDR30.44 trillion. Domestic sales contributed IDR30.82 trillion, up 7.92% fromIDR28.55 trillion and export sales of IDR1.80 trillion, down 4.49% from IDR1.88 trillion.

Sales in the domestic market were Prescription Pharmaceuticals IDR8.29 trillion, up from IDR7.45 trillion in 2023, Consumer Health IDR3.58 trillion, up from IDR3.33 trillion, Nutrition IDR8.05 trillion, up from IDR7.96 trillion, and Distribution Logistics IDR10.88 trillion, up from IDR9.80 trillion.

Export sales included Prescription Pharmaceuticals IDR927.29 billion, up from IDR7.45 trillion, Health Products IDR725.82 billion, up from IDR710.75 billion, Nutritionals IDR136.25 billion, down from IDR406.09 billion, and Distribution and Logistics IDR14.75 billion, up from IDR3.78 billion.

The company posted a gross profit of IDR12.95 trillion, up 9.59% from IDR11.82 trillion and a gross profit margin of 39.71%, up from the previous profit margin of 38.82%. Profit before income tax expense rose 16.97% to IDR4.21 trillion from IDR3.60 trillion and profit for the year grew 16.84% to IDR3.24 trillion from IDR2.77 trillion. (LK/LM)